Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive
Conditions
Interventions
None listed
Sponsors
AIIMS
Eligibility
Inclusion criteria
Inclusion criteria: It will be a prospective observational study which will include patients diagnosed with CML in chronic phase with age less than or equal to 30 years at the time of diagnosis. Patients who are on imatinib for more than 3 years, and are in MMR for more than two years, imatinib will be stopped.
Exclusion criteria
Exclusion criteria: Patient age > 30 years Patient diagnosed in CML AP/BP at baseline Patient on imatinib less than 3 years Patient in MMR for less than two years Refusal of consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine proportion of patients who are in molecular remission after stopping imatinib at the end of 6 months and 12 months.Timepoint: At 6 and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objective: 1. Identification of clinical and biological factors affecting the persistence of MMR after stopping imatinib. 2. Evaluation of quality of life (QoL) in patients after stopping imatinib and comparison with when they were on imatinib. 3. Evaluation of medico-economic impact of stopping imatinib. Timepoint: At baseline, at 6 month and 12 month | — |
Countries
India
Contacts
Public ContactDEEPAM PUSHPAM
AIIMS
Outcome results
None listed